7 Hills Pharma
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2450 Holcombe Blvd Ste J, Houston, Texas...Phone Number
(346) 772-0374Website
www.7hillspharma.comRevenue
<$5 MillionIndustry
About 7 Hills Pharma
7 Hills Pharma Inc. is a clinical-stage drug development company focused on advancing first-in-class integrin-targeted agonists to enhance the effectiveness of immunotherapies for cancer and stem cell transplantation. Their lead molecules, Alintegimod and 7HP935, aim to overcome resistance in solid tumors and improve cell-based therapies for acute leukemias and genetic disorders. The company is dedicated to making safe and effective cancer treatments accessible to all patients. With a team experienced in drug discovery and clinical development, 7 Hills Pharma is committed to transforming patient care through innovative solutions.Explore more
7 Hills Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to 7 Hills Pharma
Compare insights from companies similar to 7 Hills Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
7 Hills Pharma Tech Stack
A closer look at the technologies used by 7 Hills Pharma
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding 7 Hills Pharma
Sign Up For FreeTo access detailed company insights
7 Hills Pharma Inc. is a clinical-stage drug development company focused on advancing first-in-class integrin-targeted agonists to enhance the effectiveness of immunotherapies for cancer and stem cell transplantation. Their lead molecules, Alintegimod and 7HP935, aim to overcome resistance in solid tumors and improve cell-based therapies for acute... Read More
